Axicabtagene ciloleucel
- Generic Name
- Axicabtagene ciloleucel
- Brand Names
- Yescarta
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- U2I8T43Y7R
- Background
Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer. Once T-cells are collected from the patient, they are genetically engineered to express anti-CD19 CARs that recognize and kill canc...
- Indication
In the US, axicabtagene ciloleucel is indicated for the treatment of adults with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.
...
- Associated Conditions
- Refractory Diffuse Large B Cell Lymphoma (DLBCL), Refractory Follicular Lymphoma, Refractory Large B-cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Follicular Lymphoma, Refractory High Grade B-cell Lymphoma (HGBCL), Relapsed High Grade B-cell Lymphoma (HGBCL), Relapsed Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath